

1 **NATIONAL INSTITUTE FOR HEALTH AND CARE**
2 **EXCELLENCE**

3 **Scope for guideline update (starting 2023)**

4 **Cardiovascular disease: escalation of therapy for**
5 **secondary prevention**

6 **February 2023:** We renamed section 5 and added TA694 to the list of
related guidance.

7
8 NICE is partially updating its guideline on [cardiovascular disease: risk assessment](#)
9 [and reduction, including lipid modification](#).

10 This update of the guideline will cover treatment target(s) for escalation of lipid
11 modification therapy for secondary prevention of CVD. This is the third update as
12 part of NICE's ongoing work on our suite of cardiovascular disease guidelines.

13 The update will be developed using the methods and processes in [developing NICE](#)
14 [guidelines: the manual](#).

15 **1 Who the guideline update covers**

16 The current guideline covers adults with or without established CVD. The update will
17 focus on adults with established cardiovascular disease only.

18 The guideline does not cover people with familial hypercholesterolaemia, as they are
19 covered by the [NICE guideline on familial hypercholesterolaemia](#).

20 **Equality considerations**

21 [The equality impact assessment for the guideline update](#) lists equality issues
22 identified and how they have been addressed and explains why any populations
23 were excluded from the scope.

24 This update will look at inequalities relating to age.

2 Activities, services or aspects of care covered by the guideline update

We will look at the evidence and consider making new recommendations or updating existing recommendations on:

- Follow-up of people started on statin treatment.
- Secondary prevention: escalation of lipid modification therapy.

For all other areas of the guideline:

- There will be no evidence review.
- We will retain the existing recommendations but we may revise them to ensure consistency.

3 Draft review question

We have identified the following draft review question:

- 1 Escalation of lipid modification therapy for secondary prevention of CVD:
 - Treatment target for secondary prevention
 - 1.1 In people with established cardiovascular disease, when and to what target should lipid modification therapy be escalated?

Note that guideline recommendations for medicines will normally fall within licensed indications; exceptionally, and only if clearly supported by evidence, use outside a licensed indication may be recommended. The guideline will assume that prescribers will use a medicine's summary of product characteristics to inform decisions made with individual patients.

4 Economic aspects

We will take economic aspects into account when making recommendations. We will review the economic evidence and carry out economic analyses, using an NHS and personal social services perspective, as appropriate.

5 Related NICE guidance and quality standards

- [Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia](#) (2021) NICE technology appraisal guidance TA733
- [Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia](#) (2021) NICE technology appraisal guidance TA694
- [Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia](#) (2016) NICE technology appraisal guidance TA393
- [Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia](#) (2016) NICE technology appraisal guidance TA394
- [Ezetimibe for treating primary hypercholesterolaemia and mixed dyslipidaemia](#) (2016) NICE technology appraisal guidance TA385
- [Cardiovascular risk assessment and lipid modification](#) (2015) NICE quality standard QS100.

6 Further information

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#) and [Northern Ireland Executive](#).

The guideline update is expected to be published in September 2023.

To follow the progress of the update, see the [guideline in development page](#).

Our website has information about [how NICE guidelines are developed](#).

© NICE 2022. All rights reserved. Subject to [Notice of rights](#).